Compare · ARGX vs BTTC
ARGX vs BTTC
Side-by-side comparison of argenx SE (ARGX) and Black Titan Corporation (BTTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and BTTC operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $48.63B, about 29719.2x BTTC ($1.6M).
- Over the past year, ARGX is up 20.7% and BTTC is down 67.8% - ARGX leads by 88.5 points.
- BTTC has been more active in the news (8 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 0 for BTTC).
- Company
- argenx SE
- Black Titan Corporation
- Price
- $783.89+0.27%
- $1.24-10.79%
- Market cap
- $48.63B
- $1.6M
- 1M return
- +5.40%
- -12.06%
- 1Y return
- +20.68%
- -67.79%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 3
- 8
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Latest BTTC
- Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments
- SEC Form 6-K filed by Black Titan Corporation
- Institutional Digital Asset Infrastructure: The Maturation of Yield Routing and Restaking Rails
- SEC Form 6-K filed by Black Titan Corporation
- Crypto Payments Sector Advances as Managed Stablecoin Rails Launch, Merchant Use Cases Expand, and Regulatory Frameworks Tighten
- SEC Form 6-K filed by Black Titan Corporation
- The Institutional Stack Takes Shape: A Week of Stablecoin Infrastructure Buildout
- SEC Form 6-K filed by Black Titan Corporation
- Amendment: SEC Form F-1/A filed by Black Titan Corporation
- SEC Form 6-K filed by Black Titan Corporation